IRCT20200105046010N68招募中未知
In- Vivo Bioequivalence study of Daclaasvir/Sofosbuvir 60/400 mg Actero Middle East Pharma (DATEX 400/60 mg Tab.) with brand drug (Sofosbovir/Daclatasivir® 400/60 mg, Mylan, Germany) in Iranian healthy volunteers.
Actero middle east Pharm Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-55 years old
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
尚未招募
Unknown
Investigating the in vivo bioequivalence of Sofosbuvir/Daclatasvir tabletIn the present study, the products will be administered to healthy volunteers..IRCT20220211053992N8Tabriz University of Medical Sciences24
已完成
2 期
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1IRCT20200324046850N2Abadan University of Medical Sciences62
已完成
3 期
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000
已完成
3 期
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
已完成
不适用
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldCTRI/2020/06/025910Riten Kumar Samadder70